Investigation of the effects of intranasal botulinum toxin type a and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia

Rhinology

Volumn 46, Issue 1, 2008, Pages 45-51

  Sapci, Tarik ^a   Yazici, Sara ^b   Evcimik, M Fatih ^b   Bozkurt, Ziya ^b   Karavus, Ahmet ^b   Ugurlu, Bayram ^b   Ozkurt, Emre ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b Fatih Sultan Mehmet Training and Research Hospital   (Turkey)

Author keywords

Botulinum toxin; Hypersecretion; Idiopathic rhinitis without eosinophilia; Ipratropium bromide; Secretion

Indexed keywords

BOTULINUM TOXIN A; BRONCHODILATING AGENT; IPRATROPIUM BROMIDE; MUSCLE RELAXANT AGENT;

AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MUCUS; NOSE MUCOSA; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SECRETION; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; AGED; BOTULINUM TOXIN TYPE A; BRONCHODILATOR AGENTS; FEMALE; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; MUCUS; NASAL MUCOSA; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; RHINITIS; TREATMENT OUTCOME;

EID: 41449085187     PISSN: 03000729     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Onerci M. Rinitler. 1st ed. Ankara: Kutsan Ofset, 1999.
2. Settipane RA, Settipane GA. Nonallergic rhinitis. In: Kaliner MA, ed. Current Review of Allergic Diseases. Philadelphia: Current Medicine; 2000; 111-124.
3. The International Rhinitis Management Working Group Anonimous. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy. 1994; 49 (suppl, 14): 1-34.
4. Jones AS. Intrinsic rhinitis. In: Kerr AG, Mackay IS, Bull TR, eds. Scott Brown's Otolaryngology. 6th ed. London: Butterworth-Heinemann, 1997; 4/9/1-4/9/17
5. Fairbanks DNF, Kaliner MA. Nonallergic rhinitis and infection. In: Cummings CW, ed. Otolaryngology Head and Neck Surgery. St Louis: Mosby Year Book, 1998; 910-920.
6. Deckers W. The chemistry of new derivatives of tropane alkaloids and the pharmacakinetics of a new quaternary compound. Postgrad Med J. 1975; 51: 76-81.
7. Rominger KL. Chemistry and pharmacokinetics of ipratropium bromide. Scand J Respir Dis Suppl. 1979; 103: 116-129.
8. Kim KS, Kim SS, Yoon JH, et al. The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol. 1998; 112: 248-251.
9. Knight A, Kazim F, Salvatori VA. A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis. Ann Allergy. 1986; 57: 348-354.
10. Rohrbach S, Laskawi R. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat Spec. 2001; 63: 382-384.
11. Moore P, Naumann M. Handbook of Botulinum Toxin Treatment. 2nd ed. USA: Blackwell Science Ltd, 2003; 3-76, 343-359.
12. Raphael GD, Baraniuk JN, Kaliner MA. How and why the nose runs. J Allergy Clin Immunol. 1991; 87: 457-467.
13. Smith TL. Vasomotor rhinitis is not a wastebasket diagnosis. Arch Otolaryngol Head Neck Surg. 2003; 129: 584-587.
14. Ruffoli R, Fattori B, Giambelluca MA, Soldani P, Giannessi F. Ultracytochemical localization of the NADPH-d activity in the human nasal respiratory mucosa in vasomotor rhinitis. Laryngoscope 2000; 110: 1361-1365.
15. Golding-Wood PH. Observations on petrosal and vidian neurectomy in chronic vasomotor rhinitis. J Laryngol Otol. 1961; 75: 232-247.
16. Jaradeh SS, Smith TL, Torrico L, et al. Autonomic nervous system evaluation of patients with vasomotor rhinitis. Laryngoscope. 2000; 110: 1828-1831.
17. Kimmelman CP, Ali GHA. Vasomotor rhinitis. Otolaryngol Clin North Am. 1986; 19: 65-71.
18. Raphael GD, Meredith SD, Baraniuk JN, Kaliner MA. Nasal reflexes. Am J Rhinol. 1988; 2: 109-116.
19. Lindberg S, Malm L. Comparison of allergic rhinitis and vasomotor rhinitis patients on the basis of a computer questionnaire. Allergy. 1993; 48: 602-607.
20. Borts MR, Druce HM. The use of intranasal anticholinergic agents in the treatment of nonallergic perennial rhinitis. J Allergy Clin Immunol.1992; 90: 1065-1070.
21. Shaari CM, Sanders I, Wu BL, Biler HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg. 1995; 112: 566-571.
22. Rohrbach S, Olthoff A, Laskawi R, Giefer B, Gotz W. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol. 2001; 110: 1045-1050.
23. Unal M, Sevim S, Dogu O, et al. Effect of Botulinum Toxin Type A on Nasal Symptoms in Patients with Allergic Rhinitis: A Double- Blind, Placebo- controlled Clinical Trial. Acta Otolaryngol. 2003; 123: 1060-1063.
24. Kim KT, Kerwin E, Landwehr L, et al. Use of 0.06% ipratropium bromide nasal spray in children aged 2 to 5 years with rhinorrhea due to a common cold or allergies. Ann Allergy Asthma Immunol. 2005; 94: 73-79.
25. Wood CC, Fireman P, Grossman J, Wecker M, MacGregor T. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol. 1995; 95: 1111-1116.
26. Borum P, Mygind N, Schultz Larsen F. Intranasal ipratropium: a new treatment for perennial rhinitis. Clin Otolaryngol Allied Sci. 1979; 4: 407-411.
27. Mygind N, Borum P. Effect of a cholino-ceptor antagonist in the nose. Eur J Respir Dis Suppl. 1983; 64(128): 167-174.
28. Grossman J, Banov C, Boggs P, et al. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol. 1995; 95: 1123-1127.
29. Diamond L, Dockhorn RJ, Grossman J, et al. A dose- response study of the efficacy and safety of ipratropium bromide nasal spray in the treatment of the common cold. J Allergy Clin Immunol. 1995; 95: 1139-1146.
30. Choudry NB, Harrison AJ, Fuller RW. Inhibition of gustatory rhinorrhea by intranasal ipratropium bromide. Eur J Clin Pharmacol. 1992; 42: 561-562.
31. Druce HM, Spector SL, Fireman P, et al. Double- blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. Ann Allergy. 1992; 69: 53-60.
32. Kaiser HB, Findlay SR, Georgitis JW, et al. Long- term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol. 1995; 95: 1128-1132.
33. Scott AB, Suziki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988; 3: 333-335.
34. Bronsky EA, Druce H, Findlay SR et al. A Clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol. 1995; 95: 1117-1122.
35. Schultz Larsen F, Mygind N, Larsen FS. Ipratropium treatment for rhinorrhoea in patients with perennial rhinitis. An open follow-up study of efficacy and safety. Clin Otolaryngol Allied Sci. 1983; 8: 267-272.
36. Ohi M, Sakakura Y, Murai S, Miyoshi Y. Effect of ipratropium bromide on nasal mucociliary transport. Rhinology. 1984; 22: 241-246.
37. Savard P, Stoney PJ, Hawke M. An Anotomical study of vidian neurectomy using an endoscopic tecnique: a potential new application. J Otolaryngol. 1993; 22: 125-129.
38. Borodic GE, Ferrante RJ, Pearce LB, Alderson K. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994; 119-159.
39. Bushara KO, Park DM. Botulinum toxin and sweating. J Neurol Neurosurg Psychiatry. 1994; 57: 1437-1438.